|Bid||1.9400 x 0|
|Ask||1.9500 x 0|
|Day's Range||1.9200 - 1.9800|
|52 Week Range||0.8800 - 4.3500|
|Beta (3Y Monthly)||4.09|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 30, 2019 - May 30, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.58|
TORONTO, Aug. 14, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), an integrated cannabis company with core operations in Latin America, wishes to clarify specific disclosure relating to the news release disseminated by the Company on August 12, 2019. Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America. Khiron has core operations in Latin America and is fully licensed in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis.
Experienced capital markets leader and cannabis industry executive Tejinder Virk is appointed President of Khiron Europe Accomplished cannabis legal expert Franziska Katterbach joins Company as Chief Legal ...
Four-month pilot program with EPS SURA represents first step towards an integrated healthcare system for priority neurological pathologies EPS SURA is Colombia's leading insurance provider and an affiliate ...
As the wave of positive reviews roll in, hemp-infused beauty products containing the non-psychoactive ...